Skip to content
Brand AI

Sansure Biotech

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    Then-director Zhu Jinwei of Sansure Biotech warned by Hunan regulator for selling shares below issue price

    Zhu Jinwei, then a director of Sansure Biotech and a shareholder holding more than 5%, sold shares at a price below the issue price, breaching his commitment and failing to first return the proceeds from the违规 share reduction; he received a warning letter from the Hunan Securities Regulatory Bureau. Status: regulatory measure. Entities involved: Sansure Biotech Co., Ltd. and Zhu Jinwei. Scope: shareholder share reduction.

    Source